Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria

British Journal of Surgery

Volumn 101, Issue 5, 2014, Pages 566-572

  Merkel, S ^a   Weber, K ^a   Schellerer, V ^a   Gohl J ^a   Fietkau, R ^a   Agaimy, A ^a   Hohenberger, W ^a   Hermanek, P ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECTUM TUMOR; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS;

EID: 84896122140     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9419     Document Type: Article

References (29)

1. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, Hardcastle JD, et al,. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6: 325-344.
2. Hermanek P, Henson DE, Hutter RVP, Sobin LH, (eds). TNM Supplement 1993: a Commentary on Uniform Use. Springer: Berlin, 1993.
3. Wittekind C, Henson DE, Hutter RVP, Sobin LH, (eds). TNM Supplement: a Commentary on Uniform Use (2nd edn). Wiley: New York, 2001.
4. Wittekind C, Greene R, Hutter RVP, Sobin LH, Henson DE, (eds). TNM Supplement: a Commentary on Uniform Use (3rd edn). Wiley: New York, 2003.
5. Wittekind C, (ed.). TNM Supplement: a Commentary on Uniform Use (4th edn). Wiley-Blackwell: New York, 2012.
6. Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P,. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304.
7. Steel MC, Woods R, Mackay JM, Chen F,. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg 2002; 72: 483-487.
8. Miyoshi M, Ueno H, Hashiguchi Y, Mochizuki H, Talbot IC,. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg 2006; 243: 492-498.
9. Cianchi F, Messerini L, Comin CE, Boddi V, Perna F, Perigli G, et al,. Pathologic determinants of survival after resection of T3N0 (stage IIA) colorectal cancer: proposal for a new prognostic model. Dis Colon Rectum 2007; 50: 1332-1341.
10. Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K,. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res 2008; 28: 1773-1778.
11. Bori R, Sejben I, Svébis M, Vajda K, Markõ L, Pajkos G, et al,. Heterogeneity of pT3 colorectal carcinomas according to the depth of invasion. Pathol Oncol Res 2009; 15: 527-532.
12. Pollheimer MJ, Kornprat P, Pollheimer VS, Lindtner RA, Schlemmer A, Rehak P, et al,. Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int J Colorectal Dis 2010; 25: 187-196.
13. Shirouzu K, Akagi Y, Fujita S, Ueno H, Takii Y, Komori K, et al,.; Japanese Society for Cancer of the Colon and Rectum (JSCCR) on Clinical Significance of the Mesorectal Extension of Rectal Cancer. Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study. Ann Surg 2011; 253: 704-710.
14. Akagi Y, Shirouzu K, Fujita S, Ueno H, Takii Y, Komori K, et al,.; Study Group of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) on the Clinical Significance of the Mesorectal Extension of Rectal Cancer. Predicting oncologic outcomes by stratifying mesorectal extension in patients with pT3 rectal cancer: a Japanese multi-institutional study. Int J Cancer 2012; 131: 1220-1227.
15. Shin R, Jeong SY, Yoo HY, Park KJ, Heo SC, Kang GH, et al,. Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer. Dis Colon Rectum 2012; 55: 1220-1228.
16. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al,.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
17. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al,.; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687.
18. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J,. The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis 2006; 8: 23-33.
19. Sobin LH, Gospodarowicz MK, Wittekind C, (eds). TNM Classification of Malignant Tumours (7th edn). Wiley-Blackwell: Oxford, 2009.
20. Dworak O, Keilholz L, Hoffmann A,. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
21. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al,. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
22. Beddy D, Hyland JM, Winter DC, Lim C, White A, Moriarty M, et al,. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol 2008; 15: 3471-3477.
23. Leitlinienprogramm Onkologie; Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. S3-Leitlinie Kolorektales Karzinom, Langversion 1.0, AWMF Registrierungsnummer: 021-007OL. http://leitlinienprogramm-onkologie.de/ Leitlinien.7.0.html [accessed 1 July 2013].
24. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243: 132-139.
25. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al,. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253: 711-719.
26. Picon AI, Moore HG, Sternberg SS, Minsky BD, Paty PB, Blumberg D, et al,. Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis 2003; 18: 487-492.
27. Mrak K, Jagoditsch M, Leibl S, Klingler A, Tschmelitsch J,. Influence of pT3 subgroups on outcome of R0-resected colorectal tumors. South Med J 2011; 104: 722-730.
28. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Rectal Cancer. http://www.nccn.org/professionals/ physician-gls/pdf/rectal.pdf [accessed 1 July 2013].
29. Hermanek P, Merkel S, Hohenberger W,. Prognosis of rectal carcinoma after multimodal treatment: ypTNM classification and tumor regression grading are essential. Anticancer Res 2013; 33: 559-566.